Evidence map›Paper›PMID 41047388›Full record

ArticleScientific reports2025

Expanded CD16

Priyanka Hastak, Chansavath Phetsouphanh, Zong-Hong Zhang, Rowena A Bull, Lok Bahadur Shrestha, Vera Klemm, Raymond Louie, Fabio Luciani, C Mee Ling Munier, Alexandra Carey Hoppé and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Priyanka Hastak *The Kirby Institute, UNSW, Sydney, NSW, Australia. phastak@kirby.unsw.edu.au.
Chansavath Phetsouphanh *The Kirby Institute, UNSW, Sydney, NSW, Australia.
Zong-Hong ZhangThe Kirby Institute, UNSW, Sydney, NSW, Australia.
Rowena A BullThe Kirby Institute, UNSW, Sydney, NSW, Australia.
Lok Bahadur ShresthaThe Kirby Institute, UNSW, Sydney, NSW, Australia.
Vera KlemmClinical Trials Unit, Macquarie University, Sydney, NSW, Australia.
Raymond LouieSchool of Computer Science and Engineering, UNSW, Sydney, NSW, Australia.
Fabio LucianiSchool of Biomedical Sciences, UNSW, Sydney, NSW, Australia.
C Mee Ling MunierThe Kirby Institute, UNSW, Sydney, NSW, Australia.
Alexandra Carey HoppéThe Kirby Institute, UNSW, Sydney, NSW, Australia.
Elizabeth KeoshkerianSchool of Biomedical Sciences, UNSW, Sydney, NSW, Australia.
Brendan BeatonHaematology Department, Concord Repatriation General Hospital, Sydney, NSW, Australia.
Katherine RankinHaematology Department, Concord Repatriation General Hospital, Sydney, NSW, Australia.
Alexander WongHaematology Department, Concord Repatriation General Hospital, Sydney, NSW, Australia.
Judith TrotmanHaematology Department, Concord Repatriation General Hospital, Sydney, NSW, Australia.
Anthony D KelleherThe Kirby Institute, UNSW, Sydney, NSW, Australia.
Sarah C SassonThe Kirby Institute, UNSW, Sydney, NSW, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bruton's tyrosine kinase inhibitors (BTKi), widely used in Waldenström macroglobulinemia (WM), are known to impair B cell function, but their broader immunological effects remain unclear. We investigated the T cell compartment in patients with WM receiving BTKi, including those who underwent a supervised treatment pause before a third COVID-19 mRNA vaccine dose, as well as treatment naïve controls. Using flow cytometry, antigen-specific T cell assays, and single-cell RNA sequencing, we found that BTKi-treated patients exhibited a reduction in naïve T cells, enrichment of terminal effector CD8⁺ T

Indexed as

Agammaglobulinaemia Tyrosine KinaseCD8-Positive T-LymphocytesGranzymesKiller Cells, NaturalProtein Kinase InhibitorsWaldenstrom MacroglobulinemiaAgedCD56 AntigenCOVID-19FemaleGPI-Linked ProteinsHumansMaleMiddle AgedReceptors, IgGSARS-CoV-2Agammaglobulinaemia Tyrosine KinaseBTK protein, humanCD56 AntigenFCGR3B protein, humanGPI-Linked ProteinsGranzymesGZMB protein, humanNCAM1 protein, humanProtein Kinase InhibitorsReceptors, IgGTyrosine Kinase Inhibitors

Identifiers

PMID41047388
PMCPMC12497874

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.